The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Adverse prognostic features & treatment response in CLL
Thomas Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, comments on the use of genomics to identify poor prognostic features in chronic lymphocytic leukemia (CLL), highlighting the potential to convert a poor risk feature into a favorable risk feature with the use of targeted therapies or novel combination therapies. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
